|
|
Vaccine Detail
|
GITRL RNA-transfected Autologous Dendritic Cell Vaccine |
| Vaccine Information |
- Vaccine Name: GITRL RNA-transfected Autologous Dendritic Cell Vaccine
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007477
- Type: Recombinant vector vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- TNFSF18
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: An autologous dendritic cell (DC) cancer vaccine with potential immunostimulatory activity. GITRL RNA-transfected autologous DC vaccine is prepared by transfecting DCs with RNAs encoding tumor necrosis factor (ligand) superfamily, member 18 (TNFSF18 or GlTRL); expression of GlTRL results in modulating T lymphocyte survival in peripheral tissues. Co-vaccination of this vaccine with melanoma antigen specific vaccine may eliminate the adverse effects associated with systemic administration of immune modulators, while also enhancing vaccine-induced immune responses. (NCIT_C94216).
|
| Host Response |
|
|
| References |
NCIT_C94216: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C94216]
|
|
